Preventing the Hypoxia-Adenosinergic Inhibtion of Anti-HIV Immune Response
$251,912U19FY2013AINIH
Dana-Farber Cancer Inst, Boston MA
Investigators
Linked publications, trials & patents
Paper 30197285Paper 29308294Paper 29281817Paper 27974461Paper 27798169Paper 27466419Paper 26928033Paper 26923151Paper 26154342Paper 25938786Paper 25822926Paper 25739764Paper 25559188Paper 24990240Paper 24894061Paper 24853821Paper 24591365Paper 24531764Paper 24150416Paper 24150242Paper 24126093Paper 24075869Paper 24047898Paper 23200935Paper 22247289Paper 22002224Paper 21820024Patent 9782428Patent 9750803Patent 9445994Patent 9149432Patent 9107904Patent 12303566Patent 10029016
Abstract
It is believed that innovative adjuvants might be capable of inducing higher titers of broadly neutralizing anti-HIV-1 antibodies and better anti-HIV-1 T-cell responses. We propose to explore a novel opportunity to improve the effectiveness of anti-HIV vaccines by using anti-adenosinergic
View original record on NIH RePORTER →